Related Experiment Videos
Intravenous immunoglobulins for multiple sclerosis
The Cochrane Database of Systematic Reviews
|October 30, 2003
Summary
Intravenous immunoglobulin therapy shows promise in reducing relapses for multiple sclerosis (MS) patients. Further research is needed to confirm its effects on disease progression and utilize advanced imaging like MRI.
Area of Science:
- Neurology
- Immunology
Background:
- Animal studies suggest intravenous immunoglobulins (IVIg) may reverse central nervous system demyelination.
- Clinical trials have explored IVIg for multiple sclerosis (MS).
Purpose of the Study:
- To evaluate the safety and efficacy of IVIg in individuals with MS.
- To summarize existing evidence on IVIg for MS treatment.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) for secondary prevention of relapses and progression in MS.
- Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to 2003.
- Contacted pharmaceutical companies and trial authors for additional data.
Main Results:
- Two included trials (168 participants) indicated a reduced relapse rate and increased time to first relapse with IVIg.
- Reliable disease progression outcomes and MRI data were not reported in the included trials.
- Ongoing trials may involve up to 574 participants.
Conclusions:
- IVIg shows potential as a preventative treatment for relapses in relapsing-remitting MS.
- Further studies are recommended using MRI and disease progression endpoints.
- IVIg was generally well-tolerated with a low risk of adverse events (<5%).